AIMS: Statins are known to influence the status of adipokines, which play a key role in the pathophysiology of cardiometabolic diseases. As the effect of ezetimibe as an add-on to statin therapy on the impact of statins on plasma adipokines levels is currently unclear, the aim of the present study was to investigate this through a meta-analysis of controlled trials. METHODS: A systematic review was performed, followed by a bibliographic search in PubMed, Medline, SCOPUS, Web of Science and Google Scholar databases. Quantitative data synthesis was performed using a fixed- or random-effects model (based on the level of interstudy heterogeneity) and the generic inverse variance weighting method. Effect sizes were expressed as standardized mean difference (SMD) and 95% confidence interval (CI). RESULTS: Meta-analysis of 23 controlled trials did not suggest any significant effect of adding ezetimibe on top of statin therapy on plasma concentrations of adiponectin (SMD 0.34, 95% CI -0.28, 0.96; P = 0.288), leptin (SMD -0.75, 95% CI: -2.35, 0.85; P = 0.360), plasminogen activator inhibitor 1 (SMD -1.06, 95% CI: -2.81, 0.69; P = 0.236) and interleukin 6 (SMD 0.30, 95% CI: -0.08, 0.67; P = 0.124). However, significantly greater reductions in plasma concentrations of tumour necrosis factor α (TNF-α) (SMD -0.48, 95% CI -0.87, -0.08; P = 0.018) were achieved with ezetimibe/statin combination therapy. CONCLUSIONS: The results suggested that ezetimibe add-on to statin therapy is associated with an enhanced TNF-α-lowering effect compared with statin monotherapy. Owing to the emerging role of TNF-α in the pathogenesis of metabolic disorders, further investigations are required to unveil the translational relevance of this TNF-α-lowering effect.

Biotechnology Research Center Mashhad University of Medical Sciences Mashhad Iran

Center for the Study of Endocrine Metabolic Pathophysiology and Clinical Research University of Pavia Pavia Italy

Centre of Diabetes and Metabolic Diseases Department of Internal Medicine and Therapeutics University of Pavia and Fondazione IRCCS Policlinico San Matteo Pavia Italy

Faculty of Pharmacy in Hradec Kralove Department of Biological and Medical Sciences Charles University Hradec Kralove Czech Republic

Metabolic and Atherosclerosis Research Center Cincinnati OH USA

Molecular Medicine Laboratory University of Pavia Pavia Italy

PhD School in Experimental Medicine University of Pavia Pavia Italy

School of Medicine University of Western Australia Perth WA Australia

Zobrazit více v PubMed

Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 2016; 44 (Database Issue): D1054–D1068. PubMed PMC

Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, et al. The Concise Guide to PHARMACOLOGY 2015/16: Overview. Br J Pharmacol 2015; 172: 5729–5743. PubMed PMC

Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 2015; 172: 6024–6109. PubMed PMC

Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, et al. The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 2015; 172: 6110–6202. PubMed PMC

Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 2007; 17: 319–326. PubMed

Ritchie SA, Ewart MA, Perry CG, Connell JM, Salt IP. The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin Sci (Lond) 2004; 107: 519–532. PubMed

Von Hunolstein JJ, Nebigil CG. Can prokineticin prevent obesity and insulin resistance? Curr Opin Endocrinol Diabetes Obes 2015; 22: 367–373. PubMed

Diamant M, Lamb HJ, van de Ree MA, Endert EL, Groeneveld Y, Bots ML, et al. The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 1495–1501. PubMed

Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999; 245: 621–625. PubMed

Ukkola O, Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med (Berl) 2002; 80: 696–702. PubMed

Scotece M, Conde J, Vuolteenaho K, Koskinen A, López V, Gómez‐Reino J, et al. Adipokines as drug targets in joint and bone disease. Drug Discov Today 2014; 19: 241–258. PubMed

He G, Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Stimulation of PAI‐1 and adipokines by glucose in human adipose tissue in vitro . Biochem Biophys Res Commun 2003; 310: 878–883. PubMed

Krysiak R, Zmuda W, Marek B, Okopień B. The effect of short‐term combined treatment with simvastatin and ezetimibe on circulating adipokine levels in patients with isolated hypercholesterolemia. Endokrynol Pol 2014; 65: 275–280. PubMed

Parizadeh SM, Azarpazhooh MR, Moohebati M, Nematy M, Ghayour‐Mobarhan M, Tavallaie S, et al. Simvastatin therapy reduces prooxidant‐antioxidant balance: results of a placebo‐controlled cross‐over trial. Lipids 2011; 46: 333–340. PubMed

Sahebkar A, Catena C, Ray KK, Vallejo‐Vaz AJ, Reiner Ž, Sechi LA, et al. Impact of statin therapy on plasma levels of plasminogen activator inhibitor‐1: a systematic review and meta‐analysis of randomised controlled trials. Thromb Haemost 2016; 116: 162–171. PubMed

Sahebkar A, Simental‐Mendía LE, Pedone C, Ferretti G, Nachtigal P, Bo S, et al. Statin therapy and plasma free fatty acids: a systematic review and meta‐analysis of controlled clinical trials. Br J Clin Pharmacol 2016; 81: 807–818. PubMed PMC

Sahebkar A, Serban C, Mikhailidis DP, Undas A, Lip GYH, Muntner P, et al. Association between statin use and plasma d‐dimer levels: A systematic review and meta‐analysis of randomised controlled trials. Thrombosis and Haemostasis 2015; 114: 546–557. PubMed

Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on paraoxonase‐1 status: a systematic review and meta‐analysis of 25 clinical trials. Prog Lipid Res 2015; 60: 50–73. PubMed

Sahebkar A, Ponziani MC, Goitre I, Bo S. Does statin therapy reduce plasma VEGF levels in humans? A systematic review and meta‐analysis of randomized controlled trials. Metabolism 2015; 64: 1466–1476. PubMed

Sahebkar A, Kotani K, Serban C, Ursoniu S, Mikhailidis DP, Jones SR, et al. for the Lipid and Blood Pressure Meta‐analysis Collaboration (LBPMC) GroupStatin therapy reduces plasma endothelin‐1 concentrations: a meta‐analysis of 15 randomized controlled trials. Atherosclerosis 2015; 241: 433–442. PubMed

Krysiak R, Labuzek K, Okopien B. Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol Rep 2009; 61: 1134–1145. PubMed

Krysiak R, Zmuda W, Okopien B. The effect of short‐term simvastatin treatment on plasma adipokine levels in patients with isolated hypercholesterolemia: a preliminary report. Pharmacol Rep 2014; 66: 880–884. PubMed

Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co‐administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004; 93: 1487–1494. PubMed

Battaggia A, Donzelli A, Font M, Molteni D, Galvano A. Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: systematic review and meta‐analysis of randomized controlled trials. PLoS One 2015; 10: e0124587. PubMed PMC

Berthold HK, Berneis K, Mantzoros CS, Krone W, Gouni‐Berthold I. Effects of simvastatin and ezetimibe on interleukin‐6 and high‐sensitivity C‐reactive protein. Scand Cardiovasc J Suppl 2013; 47: 20–27. PubMed

Blanco‐Colio LM, Martín‐Ventura JL, Gómez‐Guerrero C, Masramon X, de Teresa E, Farsang C, et al. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. Eur J Pharmacol 2008; 586: 259–265. PubMed

Hu Y, Tong G, Xu W, Pan J, Ryan K, Yang R, et al. Anti‐inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis. Diab Vasc Dis Res 2009; 6: 262–268. PubMed

Kurobe H, Aihara K, Higashida M, Hirata Y, Nishiya M, Matsuoka Y, et al. Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress. J Atheroscler Thromb 2011; 18: 1080–1089. PubMed

Sun YM, Li J, Luan Y, Wang LF. Effect of statin therapy on leptin levels in patients with coronary heart disease. Peptides 2010; 31: 1205–1207. PubMed

Takase H, Dohi Y, Okado T, Hashimoto T, Goto Y, Kimura G. Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study. Eur J Clin Invest 2012; 42: 1287–1294. PubMed

Gouni‐Berthold I, Berthold HK, Chamberland JP, Krone W, Mantzoros CS. Short‐term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol (Oxf) 2008; 68: 536–541. PubMed

Kater AL, Batista MC, Ferreira SR. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. Metabolism 2010; 59: 921–926. PubMed

Otto C, Otto B, Frost RJ, Vogeser M, Pfeiffer AF, Spranger J, et al. Short‐term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetol 2007; 44: 65–68. PubMed

Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, et al. Efficacy of long‐term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101–107. PubMed

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. BMJ 2009; 339: b2535. PubMed PMC

Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. London: The Cochrane Collaboration, 2009.Version 5.0.2

Borenstein M, Hedges L, Higgins J. Comprehensive Meta‐Analysis. Englewood, NJ: Biostat, 2005.Version 2

Sahebkar A, Rathouska J, Derosa G, Maffioli P, Nachtigal P. Statin impact on disease activity and C‐reactive protein concentrations in systemic lupus erythematosus patients: a systematic review and meta‐analysis of controlled trials. Autoimmun Rev 2016; 15: 344–353. PubMed

Banach M, Serban C, Sahebkar A, Mikhailidis DP, Ursoniu S, Ray KK, et al. Impact of statin therapy on coronary plaque composition: a systematic review and meta‐analysis of virtual histology intravascular ultrasound studies. BMC Med 2015; 13: 229. PubMed PMC

Sahebkar A. A systematic review and meta‐analysis of the effects of pycnogenol on plasma lipids. J Cardiovasc Pharmacol Ther 2014; 19: 244–255. PubMed

Derosa G, Maffioli P, Sahebkar A. Improvement of plasma adiponectin, leptin and C‐reactive protein concentrations by orlistat: a systematic review and meta‐analysis. Br J Clin Pharmacol 2016; 81: 819–834. PubMed PMC

Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta‐analysis of randomized placebo‐controlled trials. Pharmacol Res 2015; 102: 63–70. PubMed

Banach M, Serban C, Ursoniu S, Rysz J, Muntner P, Toth PP, et al. for the Lipid and Blood Pressure Meta‐analysis Collaboration (LBPMC) GroupStatin therapy and plasma coenzyme Q10 concentrations – a systematic review and meta‐analysis of placebo‐controlled trials. Pharmacol Res 2015; 99: 329–336. PubMed

Sahebkar A. Are curcuminoids effective C‐reactive protein‐lowering agents in clinical practice? Evidence from a meta‐analysis. Phytother Res 2014; 28: 633–642. PubMed

Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13. PubMed PMC

Duval S, Tweedie R. Trim and fill: a simple funnel‐plot‐based method of testing and adjusting for publication bias in meta‐analysis. Biometrics 2000; 56: 455–463. PubMed

Lee SH, Kang SM, Park S, Jang Y, Chung N, Choi D. The effects of statin monotherapy and low‐dose statin/ezetimibe on lipoprotein‐associated phospholipase A2 . Clin Cardiol 2011; 34: 108–112. PubMed PMC

Yagi S, Akaike M, Aihara K, Iwase T, Ishikawa K, Yoshida S, et al. Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. J Atheroscler Thromb 2010; 17: 173–180. PubMed

Almquist T, Jacobson SH, Mobarrez F, Näsman P, Hjemdahl P. Lipid‐lowering treatment and inflammatory mediators in diabetes and chronic kidney disease. Eur J Clin Invest 2014; 44: 276–284. PubMed

Dawson JA, Choke E, Loftus IM, Cockerill GW, Thompson MM. A randomised placebo‐controlled double‐blind trial to evaluate lipid‐lowering pharmacotherapy on proteolysis and inflammation in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2011; 41: 28–35. PubMed

Ferreira CE, França CN, Izar MC, Camargo LM, Roman RM, Fonseca FA. High‐intensity statin monotherapy versus moderate‐intensity statin plus ezetimibe therapy: effects on vascular biomarkers. Int J Cardiol 2015; 180: 78–79. PubMed

Florentin M, Liberopoulos EN, Tellis CC, Derdemezis CS, Elisaf M, Tselepis A. Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study. Angiology 2010; 61: 365–371. PubMed

Habara M, Nasu K, Terashima M, Ko E, Yokota D, Ito T, et al. Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe. Am J Cardiol 2014; 113: 580–587. PubMed

Hajer GR, Dallinga‐Thie GM, van Vark‐van der Zee LC, Olijhoek JK, Visseren FL. Lipid‐lowering therapy does not affect the postprandial drop in high density lipoprotein‐cholesterol (HDL‐c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial. Clin Endocrinol (Oxf) 2008; 69: 870–877. PubMed

Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B‐100 kinetics in insulin‐resistant obese subjects on a weight loss diet. Diabetes Care 2010; 33: 1134–1139. PubMed PMC

Kater AL, Batista MC, Ferreira SR. Synergistic effect of simvastatin and ezetimibe on lipid and pro‐inflammatory profiles in pre‐diabetic subjects. Diabetol Metab Syndr 2010; 2: 34. PubMed PMC

Kikuchi K, Nezu U, Inazumi K, Miyazaki T, Ono K, Orime K, et al. Double‐blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. J Atheroscler Thromb 2012; 19: 1093–1101. PubMed

Kovarnik T, Mintz GS, Skalicka H, Kral A, Horak J, Skulec R, et al. Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study. Circ J 2012; 76: 176–183. PubMed

Krysiak R, Zmuda W, Okopień B. The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia. Fundam Clin Pharmacol 2012; 26: 424–431. PubMed

Krysiak R, Zmuda W, Okopien B. The effect of ezetimibe on adipose tissue hormones in patients with isolated hypercholesterolemia. Pharmacol Rep 2014; 66: 442–447. PubMed

Krysiak R, Zmuda W, Okopien B. The effect of simvastatin‐ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia. Cardiovasc Ther 2014; 32: 40–46. PubMed

Liu LQ. Comparative study of high‐dose Xuezhikang and low‐dose Xuezhikang plus ezetimibe on pro‐ and anti‐inflammatory markers. Clin Lipidol 2013; 8: 151–157.

Rudofsky G, Reismann P, Groener JB, Djuric Z, Fleming T, Metzner C, et al. Identical LDL‐cholesterol lowering but non‐identical effects on NF‐kappaB activity: high dose simvastatin vs combination therapy with ezetimibe. Atherosclerosis 2012; 223: 190–196. PubMed

Takeshita Y, Takamura T, Honda M, Kita Y, Zen Y, Kato K, et al. The effects of ezetimibe on non‐alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 2014; 57: 878–890. PubMed

Undas A, Machnik A, Potaczek DP, Wypasek E, Zmudka K, Tracz W. Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events. J Cardiovasc Pharmacol 2011; 58: 167–172. PubMed

Yamazaki D, Ishida M, Watanabe H, Nobori K, Oguma Y, Terata Y, et al. Comparison of anti‐inflammatory effects and high‐density lipoprotein cholesterol levels between therapy with quadruple‐dose rosuvastatin and rosuvastatin combined with ezetimibe. Lipids Health Dis 2013; 12: 9. PubMed PMC

Mihos CG, Pineda AM, Santana O. Cardiovascular effects of statins, beyond lipid‐lowering properties. Pharmacol Res 2014; 88: 12–19. PubMed

Pasterkamp G, van Lammeren GW. Pleiotropic effects of statins in atherosclerotic disease. Expert Rev Cardiovasc Ther 2010; 8: 1235–1237. PubMed

Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag 2008; 4: 341–353. PubMed PMC

Sinzinger H, Wolfram R, Peskar BA. Muscular side effects of statins. J Cardiovasc Pharmacol 2002; 40: 163–171. PubMed

Michalska‐Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP, et al. for the Lipid and Blood Pressure Meta‐analysis Collaboration (LBPMC) GroupAnalysis of vitamin D levels in patients with and without statin‐associated myalgia – a systematic review and meta‐analysis of 7 studies with 2420 patients. Int J Cardiol 2015; 178: 111–116. PubMed

Kosoglou T, Statkevich P, Johnson‐Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005; 44: 467–494. PubMed

Pascual Izuel JM, Rodilla Sala E, Sánchez Juan C. Clinical efficacy of ezetimibe and combined use with statins. Rev Clin Esp 2005; 205: 496–498. PubMed

Gupta M, Szmitko PE, Tsigoulis M, Braga MF, Kajil M, Herjikaka S, et al. Effects of ezetimibe add‐on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease. J Cardiovasc Pharmacol 2010; 56: 241–245. PubMed

Xu H, Uysal KT, Becherer JD, Arner P, Hotamisligil GS. Altered tumor necrosis factor‐alpha (TNF‐alpha) processing in adipocytes and increased expression of transmembrane TNF‐alpha in obesity. Diabetes 2002; 51: 1876–1883. PubMed

Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor‐alpha: direct role in obesity‐linked insulin resistance. Science 1993; 259: 87–91. PubMed

Coppack SW. Pro‐inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001; 60: 349–356. PubMed

Klover PJ, Clementi AH, Mooney RA. Interleukin‐6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005; 146: 3417–3427. PubMed

Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 2010; 17: 332–341. PubMed

Bułdak Ł, Machnik G, Bułdak RJ, Łabuzek K, Bołdys A, Okopień B. Exenatide and metformin express their anti‐inflammatory effects on human monocytes/macrophages by the attenuation of MAPKs and NFkappaB signaling. Naunyn Schmiedebergs Arch Pharmacol 2016; 389: 1103–1115. PubMed

Del Porto F, Laganà B, Lai S, Nofroni I, Tinti F, Vitale M, et al. Response to anti‐tumour necrosis factor alpha blockade is associated with reduction of carotid intima‐media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1111–1115. PubMed

Cao YY, Chen ZW, Gao YH, Wang XX, Ma JY, Chang SF, et al. Exenatide reduces tumor necrosis factor‐alpha‐induced apoptosis in cardiomyocytes by alleviating mitochondrial dysfunction. Chin Med J (Engl) 2015; 128: 3211–3218. PubMed PMC

Link A, Ayadhi T, Böhm M, Nickenig G. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J 2006; 27: 2945–2955. PubMed

Xie W, Li P, Wang Z, Chen J, Lin Z, Liang X, et al. Rosuvastatin may reduce the incidence of cardiovascular events in patients with acute coronary syndromes receiving percutaneous coronary intervention by suppressing miR‐155/SHIP‐1 signaling pathway. Cardiovasc Ther 2014; 32: 276–282. PubMed

Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease. J Cardiol 2009; 53: 317–333. PubMed

Bahceci M, Gokalp D, Bahceci S, Tuzcu A, Atmaca S, Arikan S. The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin‐6 and high sensitivity C‐reactive protein levels. Is adipocyte size associated with inflammation in adults? J Endocrinol Invest 2007; 30: 210–214. PubMed

Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, et al. Achievement of dual low‐density lipoprotein cholesterol and high‐sensitivity C‐reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE‐IT. Circulation 2015; 132: 1224–1233. PubMed

Wang X, Zhao X, Li L, Yao H, Jiang Y, Zhang J. Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart Lung Circ 2016; 25: 459–465. PubMed

Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, et al. for the PRECISE‐IVUS InvestigatorsImpact of dual lipid‐lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE‐IVUS trial. J Am Coll Cardiol 2015; 66: 495–507. PubMed

Crea F, Niccoli G. Ezetimibe and plaque regression: cholesterol lowering or pleiotropic effects? J Am Coll Cardiol 2015; 66: 508–510. PubMed